ClinicalTrials.gg
RecruitingNCT07861204Updated Oct 6, 2026

Combination of Rituximab and Cyclosporine in the Treatment of Primary Membranous Nephropathy

A Phase 2/3 interventional study of Rituximab combined with cyclosporine and rituximab in Membranous Nephropathy, sponsored by Peking University First Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Peking University First Hospital · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing rituximab in Glomerulonephritis, Membranous — 7 open to participants now, 8 under way, 4 of them phase 3. Rituximab · Glomerulonephritis, Membranous.

Planned enrollment
5th of 15
90 · median 78
Started
2026
the only one that year
Phase 2/3
3 of 15
1 open now
Registered
15th of 15
by date
Lead sponsor
1 of 15
Peking University First Hospital

Among the 15 studies testing rituximab in Glomerulonephritis, Membranous, this one is the 5th largest by planned enrollment, is the only one that started in 2026, is one of 3 in phase 2/3, and was the 15th registered.

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

Browse Glomerulonephritis, Membranous studies →

Open to participants now

7 of the 15 studies testing rituximab in Glomerulonephritis, Membranous are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 13 (32%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing rituximab in Glomerulonephritis, Membranous, or all of them as a file.
02

Study summary

High-grade proteinuria is one of the key determinants of adverse renal prognosis in patients with primary membranous nephropathy (PMN).The main purpose of this study is to determine whether Rituximab combined with Cyclosporine is superior to Rituximab monotherapy in inducing remission of proteinuria in patients with PMN.

Read the detailed description

Primary membranous nephropathy (PMN) is one of the most common causes of nephrotic syndrome among Chinese adults. For patients with high-grade proteinuria , immunosuppressive therapy is needed. B cell-depleting agent Rituximab is a recommended treatment Regimen in maintaining remission but the response to Rituximab is relatively slow. Calcineurin inhibitors lead to earlier reductions in proteinuria but presenting higher relapse rates in the long follow-up period.Combination therapy may provide both earlier proteinuria remission and durable effect. This is a multi-center, randomized, open-label study conducted in adult patients with biopsy-proven PMN. The main purpose of this study is to determine whether Rituximab combined with Cyclosporine is superior to Rituximab monotherapy in inducing remission of proteinuria in patients with PMN.

03

Conditions studied

  • Membranous Nephropathy

Keywords

  • membranous nephropathy
  • Rituximab
  • Cyclosporine
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80 years.
  2. Primary membranous nephropathy confirmed by renal .
  3. 24-hour urinary protein quantification > 5.0 g/24h and serum albumin \< 30 g/L after at least 3 months of treatment with RAAS blockers.
  4. ≥ 40 mL/min/1.73 m².
  5. Well-controlled blood pressure (≤140/90 mmHg) in the recent 3 months.
  6. Signed form.

Exclusion criteria

Exclusion Criteria:

  1. Secondary causes of membranous nephropathy, such as that secondary to systemic lupus erythematosus, malignant tumors, virus infection, heavy metal poisoning;
  2. Coexistence of other types of kidney diseases;
  3. Use of rituximab within the past 12 months;
  4. Use of , cyclophosphamide, cyclosporine, mycophenolate mofetil, or leflunomide within the past 3 months;
  5. Active infection: active tuberculosis, HBsAg positivity or HBV-DNA indicating viral replication, positive antibody, infection;
  6. New-onset cardiovascular or cerebrovascular diseases within the past 3
  7. Severe liver disease: and ALT > 3 times range upper limit ;
  8. Uncontrolled severe hypertension;
  9. Newly diagnosed or recurrent malignant tumors within the past 5 years;
  10. Coexistent diseases;
  11. Pregnancy, lactation, or recent plans for pregnancy;
  12. less than 12 months;
  13. Participation in other clinical trials within the past 3 months;
  14. Unwillingness to sign the form;
  15. Any other condition deemed unsuitable for the study by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    combination therapy

    Rituximab combined with cyclosporine

    Drug: Rituximab combined with cyclosporine

  • Active comparator
    monotherapy

    Rituximab

    Drug: rituximab

Interventions

  • DrugRituximab combined with cyclosporine

    Drug pages: RituximabStudies of RituximabRituximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CyclosporineStudies of CyclosporineCyclosporine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The first cycle of rituximab was given at a dose of 1000 mg i.v. on day 1 and day 15.Patients were retreated with rituximab (1000mg ) when CD20 B-cell count was more than 5 cells/ml.Oral cyclosporine will be started at 3 mg/kg/day and continued for 6 months, followed by a 2-month tapering period.

  • The first cycle of rituximab was given at a dose of 1000 mg i.v. on day 1 and day 15.Patients were retreated with rituximab (1000mg ) when CD20 B-cell count was more than 5 cells/ml.

06

What researchers measure

Primary outcomes

  1. Remission Status

    the proportion of subjects to reach the composite of maintaining complete remission or partial remission at 3 months after randomization

    Time frame: At 3 months after randomization

Secondary outcomes

  1. Remission at 6 months and 12 months

    The proportions of patients achieving complete remission or partial remission at 6 and 12 months of treatment.

    Time frame: From enrollment to the end of follow-up at 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Oct 6, 2026
StartActual
Jan 21, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07861204
Collaborators
China Rehabilitation Research Center, Fu Xing Hospital, Capital Medical University, People's Hospital of Beijing Daxing District
Responsible party
Zhao CUI (MD, Peking University First Hospital) — Principal investigator
First posted
Oct 6, 2026
Start date
Jan 21, 2026
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Fang Wang, Doctor
Contact
wangfang@bjmu.edu.cn
01083572388

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rituximab · Cyclosporine

Start the discussion